NVP BGJ398 phosphate
- Product Name
- NVP BGJ398 phosphate
- CAS No.
- 1310746-10-1
- Chemical Name
- NVP BGJ398 phosphate
- Synonyms
- BGJ-398 phosphate;BGJ 398 phosphate;NVP BGJ398 phosphate;NVP-BGJ398 (phosphate);Infigratinib phosphate;BGJ-398,NVP-BGJ398,Infigratinib;Infigratinib (BGJ-398) phosphate;Infigratinib phosphate, 10 mM in DMSO;INFIGRATINIB PHOSPHATE;BGJ-398 PHOSPHATE;NVP-BGJ398 phosphate (Infigratinib phosphate
- CBNumber
- CB52666670
- Molecular Formula
- C26H34Cl2N7O7P
- Formula Weight
- 658.47
- MOL File
- 1310746-10-1.mol
NVP BGJ398 phosphate Property
- storage temp.
- Store at -20°C
- solubility
- insoluble in EtOH; ≥28.07 mg/mL in H2O with gentle warming and ultrasonic; ≥95.7 mg/mL in DMSO
- form
- Powder
- color
- White to gray
- InChIKey
- GUQNHCGYHLSITB-UHFFFAOYSA-N
- SMILES
- P(O)(O)(O)=O.N(C1C(=C(OC)C=C(OC)C=1Cl)Cl)C(=O)N(C1=NC=NC(NC2C=CC(N3CCN(CC)CC3)=CC=2)=C1)C
N-Bromosuccinimide Price
- Product number
- CS-1559
- Product name
- Infigratinibphosphate
- Purity
- 97.74%
- Packaging
- 10mg
- Price
- $70
- Updated
- 2021/12/16
- Product number
- orb611817
- Product name
- NVP-BGJ398 phosphate
- Packaging
- 10mg
- Price
- $217.6
- Updated
- 2021/12/16
- Product number
- CS-1559
- Product name
- Infigratinibphosphate
- Purity
- 97.74%
- Packaging
- 5mg
- Price
- $50
- Updated
- 2021/12/16
- Product number
- orb611817
- Product name
- NVP-BGJ398 phosphate
- Packaging
- 50mg
- Price
- $385.9
- Updated
- 2021/12/16
- Product number
- orb611817
- Product name
- NVP-BGJ398 phosphate
- Packaging
- 100mg
- Price
- $482.8
- Updated
- 2021/12/16
NVP BGJ398 phosphate Chemical Properties,Usage,Production
Uses
Infigratinib phosphate (BGJ-398 phosphate; NVP-BGJ398 phosphate) is a potent inhibitor of the FGFR family with IC50 of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.
Biological Activity
ic50 value: 0.9 nm (fgfr1); 1.4 nm (fgfr2); 1 nm (fgfr2) [1] nvp-bgj398 is a novel selective, pan-specific fgfr inhibitor currently in phase i
in vivo
Infigratinib is administered to athymic nude mice implanted subcutaneously with RT112/luc1 tumors: either as a 5 mg/kg intravenous bolus in NMP/PEG200 (1:9, v/v) or orally by gavage as a suspension in PEG300/D5W (2:1, v/v) at a 20 mg/kg dose. The relevant pharmacokinetic (PK) parameters indicate that the oral bioavailability of Infigratinib in this study is 32%. After intravenous dosing, Infigratinib shows a rapid distribution from the vascular compartment into the peripheral tissues, translating into a high volume of distribution (26 L/kg). The plasma clearance is high at 3.3 L/h/kg (61% of liver blood flow). The ratio of tumor to plasma after oral dosing based on AUC is determined to be 10[1]. Infigratinib (30 mg/kg) significantly inhibits the growth of FGFR2-mutated endometrial cancer xenograft models[2].
IC 50
FGFR1: 0.9 nM (IC50); FGFR2: 1.4 nM (IC50); FGFR3: 1 nM (IC50); FGFR4: 60 nM (IC50)
References
[1] Guagnano V, et al. Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-me thyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor T DOI:10.1021/jm2006222
[2] Konecny GE, et al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol Cancer Ther. 2013 May;12(5):632-42. DOI:10.1158/1535-7163.MCT-12-0999
NVP BGJ398 phosphate Preparation Products And Raw materials
Raw materials
Preparation Products
NVP BGJ398 phosphate Suppliers
- Tel
- --
- Fax
- --
- info@axonmedchem.com
- Country
- The Netherlands
- ProdList
- 477
- Advantage
- 30